
One blood draw, ordered and reviewed by a board-certified physician, screening for a shared cancer signal across more than 50 cancer types. Many of these cancers have no recommended screening today.
Self-pay $1,150. Complements your standard screenings. It does not replace them.
Joint Commission AccreditedGalleri, made by GRAIL, is a blood-based test that looks for a single shared cancer signal across more than 50 cancer types. It reads DNA methylation patterns in cell-free DNA, the genetic fragments cancer sheds into the bloodstream. When a signal is found, the test also predicts where in the body it most likely came from.
The draw takes about ten minutes at our Surfside clinic, two small tubes of blood. GRAIL analyzes the sample, and results return in roughly two weeks. You review them in person or by telehealth with a TrufaMED physician, who explains what the result means and what, if anything, comes next. This is a screening tool, not a diagnosis, and it is most useful for the cancers that current screening programs miss entirely.
Galleri is built around a focused workup. Because the test predicts a likely tissue of origin, a positive result points your physician toward a specific next step rather than a body-wide search.
Two tubes drawn into GRAIL’s preservatives at our Surfside lab. About ten minutes, no fasting or prep required.
GRAIL examines methylation patterns in your cell-free DNA to look for a shared cancer signal. Results return in roughly two weeks.
Your TrufaMED physician reviews the full report with you, in person or by telehealth, and explains exactly what it shows.
If a signal is detected, imaging is chosen to match the predicted origin, and we coordinate any referrals and specialist care from there.
Mammography, colonoscopy, low-dose CT, Pap, and PSA are essential, and Galleri replaces none of them. Its value is the cancers that have no recommended screening at all, where most cases are found late.
Roughly 70 percent of cancer deaths in the United States are from cancers without a recommended screening test. For many of those, a person has no way to catch the disease early, because there is simply nothing to look with. Galleri adds a blood-based signal for that gap, and it can shift detection to an earlier stage where treatment options are broader.
No effective population screening exists. Galleri can surface a signal before the typical late, symptomatic presentation.
Survival drops sharply from early to late stage. Catching a signal earlier genuinely changes the path of care.
Rising incidence and aggressive biology, with endoscopy too invasive to serve as a population-level screen.
Often silent until advanced, with no recommended screening for average-risk adults in the United States.
Oropharyngeal and laryngeal cancers are routinely found in symptomatic stages, with no dedicated screening pathway.
Galleri screens for a signal across more than 50 cancer types in a single draw, far beyond what routine screening covers.
Galleri is designed for adults at higher risk, where adding detection capability for unscreened cancers is most valuable. A physician confirms it fits your situation before you test.
The test is intended for adults aged 50 and older, the group with the highest baseline cancer risk. It is also appropriate for adults under 50 who carry elevated risk: a strong family history of cancer, a known cancer-predisposition mutation, a prior cancer history, or heavy environmental exposure. Your TrufaMED physician evaluates your history and decides whether Galleri makes sense for you.
Adults 50 and older who want detection beyond standard screening, people with a strong family history of cancer, individuals with a known genetic predisposition such as a BRCA or Lynch syndrome mutation, cancer survivors monitoring for a second primary cancer alongside their oncologist, and health-conscious adults who want the fullest picture of their risk. If you are weighing inherited risk, our Empower hereditary cancer screening and Horizon genetic carrier screening look at the genes you were born with, while Galleri looks for a signal of cancer that may be present now. Many patients use them together.
Whether or not Galleri finds a signal, keep every recommended screening on schedule: your mammogram, colonoscopy, cervical screening, low-dose CT, and PSA where indicated. Galleri adds to the standard of care, it does not stand in for it. See how it fits into your broader preventive care plan.
Galleri rests on one of the largest evidence bases in cancer screening, and at TrufaMED every step is led by a board-certified MD, not a mail-in kit.
Galleri’s development includes the Circulating Cell-Free Genome Atlas studies, the PATHFINDER cohort, the PATHFINDER 2 registrational study of 35,878 participants, and the NHS-Galleri trial in the United Kingdom with more than 140,000 participants.
When a signal is found, Galleri predicts the most likely tissue of origin, so the diagnostic workup is targeted to one organ system rather than a broad, anxious search across the whole body.
Every order, interpretation, and follow-up at TrufaMED is delivered by a board-certified physician at a Joint Commission-accredited, CLIA-certified facility, the only one in Florida.
Galleri is a CLIA Laboratory Developed Test, not FDA-approved, and it is one screening tool among several. We explain the false-positive rate and what the test cannot tell you before you decide.
The draw happens at our own diagnostic lab, and if follow-up is needed, on-site digital X-ray and coordinated imaging keep your workup moving without delay.
Galleri pairs naturally with a concierge membership, where annual screening, results review, and coordination are handled by a physician who knows your full history.
Galleri is self-pay, with a single price set by GRAIL. Your visit includes the physician work that makes the result meaningful.
Galleri is not currently covered by commercial or Medicare insurance. The price is set by GRAIL. The test is HSA and FSA eligible when ordered by a physician, which we do as a standard part of the workflow. Follow-up imaging or specialist referrals, if a cancer signal is detected, are billed separately. Questions about coverage? See our insurance page.
A cancer-screening result is only as useful as the physician who interprets it. At TrufaMED, two board-certified MDs order and review every Galleri test.
Dr. Gedalia earned his medical degree from Louisiana State University and completed his surgical residency at St. Vincent’s Hospital in New York. His surgical and oncologic experience shapes how TrufaMED interprets a cancer signal and coordinates the imaging, biopsy, and specialist care that may follow.
Dr. Naidoo brings extensive adult and pediatric emergency, trauma, and critical-care experience from high-volume emergency departments across the East Coast. He brings calm, clear judgment to a sensitive result, walking you through what it means and what to do next.
TrufaMED carries Joint Commission accreditation, a distinction held by only eight urgent care centers in the United States. It is the same standard applied to major hospitals, and it governs every part of our diagnostic and screening work.
What patients across Miami, Miami Beach, Bal Harbour, and Surfside ask before testing.
It means Galleri identified DNA methylation patterns consistent with cancer in your blood sample, and predicts a Cancer Signal Origin, the most likely tissue of origin. This is not a diagnosis. It is a strong indication that targeted diagnostic workup is needed. Your TrufaMED physician reviews the report with you, explains the predicted origin, and coordinates the focused imaging and referrals specific to that organ system.
No. Galleri is offered as a Laboratory Developed Test under CLIA certification by GRAIL. It is not currently FDA-approved or cleared. Performance data comes from GRAIL’s CCGA, PATHFINDER, and STRIVE studies. Your physician will explain what the test can and cannot tell you before you decide to proceed.
In GRAIL’s published data, the false-positive rate is roughly 0.5 percent, meaning about 1 in 200 people without cancer will receive a Cancer Signal Detected result that does not correspond to cancer on workup. We discuss this clearly before testing so you understand the possibility going in.
Not currently. Galleri is self-pay only at $1,150, a price set by GRAIL. The test is HSA and FSA eligible when ordered by a physician, which TrufaMED does as a standard part of the workflow.
No. Galleri is complementary to standard cancer screening, not a replacement. Mammography, colonoscopy, cervical screening, low-dose CT, and PSA where indicated remain the standard of care. Galleri adds detection for many cancers that have no routine screening test at all.
GRAIL’s recommended cadence is annual testing for adults 50 and older at elevated risk. Your TrufaMED physician personalizes the cadence based on your overall risk profile, family history, and prior results.
About 10 minutes total for the visit. Two tubes of blood are drawn into the special preservatives GRAIL provides, then shipped to the GRAIL laboratory. Results typically return in about two weeks, and you review them with a TrufaMED physician.
Yes, with a physician evaluation. Patients with a strong family history of cancer, a known cancer-predisposition mutation, a prior cancer history, or heavy environmental risk factors are reasonable candidates under 50. Your TrufaMED physician determines clinical appropriateness for your situation.
This can happen, given the roughly 0.5 percent false-positive rate. If follow-up imaging and workup find no cancer, we typically recommend repeating Galleri in 12 months and continuing your standard-of-care screening on schedule. Your physician guides the plan and stays involved throughout.
GRAIL is HIPAA compliant and does not share identifiable data with third parties without your consent. The federal GINA law prevents health insurance and employment discrimination based on genetic test results, though GINA does not extend to life, disability, or long-term care insurance. Your physician reviews these protections with you before testing.
Galleri is an investigational Laboratory Developed Test offered under CLIA, not FDA-approved. It does not detect all cancers and a negative result does not rule cancer out. Continue all recommended screenings. For a true emergency, call 911.
Best clinic ever
Excellent. Attentive clean
The staff is very nice and courteous
Very nice receptionist
Best place I’ve been to by far great service
The staff are amazing, from front desk, registration, nurse , the Dr. A mean the facility very clean, conftuble, I'll give them 150% plus on everything and all. Thank you so very much
Galleri is a CLIA-validated multi-cancer early detection test, ordered by a physician and used alongside standard cancer screening, not instead of it. These independent sources are offered for further reading.
Monday–Friday 9 AM – 9 PM
Saturday 11 AM – 11 PM
Sunday 12 PM – 8 PM
Galleri draws are scheduled with a physician consult.
Phone (305) 537-6396
WhatsApp +1 (305) 842-9801
Email [email protected]
For a life-threatening emergency, call 911. TrufaMED treats non-life-threatening conditions.
Talk with a TrufaMED physician about whether Galleri multi-cancer early detection is right for you. One conversation, one blood draw, a clearer picture of your health.
Notes from your physicians, every other week.
Seasonal health for South Florida, what we are seeing at the clinic, and the occasional thing worth knowing. No spam, and you can leave anytime.
Book urgent care, IV therapy, HBOT and telehealth, track your wellness, and reach your care team, all from the app.
Book visits, IV therapy and HBOT, start a telehealth visit, and reach your care team, right from your iPhone.
Download on theApp Store